
Biodesix Inc
NASDAQ:BDSX

Operating Margin
Biodesix Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
![]() |
Biodesix Inc
NASDAQ:BDSX
|
52.7m USD |
-43%
|
|
US |
![]() |
Cigna Corp
NYSE:CI
|
82.1B USD |
4%
|
|
US |
C
|
Cigna Group
XMUN:CGN
|
68.4B EUR |
4%
|
|
US |
![]() |
CVS Health Corp
NYSE:CVS
|
78.1B USD |
3%
|
|
DE |
![]() |
Fresenius Medical Care AG
XMUN:FME
|
26.9B EUR |
7%
|
|
DE |
![]() |
Fresenius SE & Co KGaA
XETRA:FRE
|
23.6B EUR |
9%
|
|
US |
![]() |
Laboratory Corporation of America Holdings
NYSE:LH
|
20.9B USD |
9%
|
|
US |
![]() |
Quest Diagnostics Inc
NYSE:DGX
|
19B USD |
14%
|
|
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
13.4B EUR |
7%
|
|
US |
![]() |
Hims & Hers Health Inc
NYSE:HIMS
|
12.9B USD |
6%
|
|
US |
![]() |
DaVita Inc
NYSE:DVA
|
11.7B USD |
15%
|
Biodesix Inc
Glance View
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biodesix Inc's most recent financial statements, the company has Operating Margin of -43.5%.